8-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2002

Date of Filing: June 18, 2002

Lynx Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

0-22570
(Commission File No.) 94-3161073
(IRS Employer Identification No.)

25861 Industrial Blvd.
Hayward, California 94545
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (510) 670-9300

TABLE OF CONTENTS

	Item 5. Other Events
	Item 7. Financial Statements and Exhibits
INDEX TO EXHIBITS
SIGNATURE
EXHIBIT 99.1
EXHIBIT 99.2

Item 5. Other Events

On June 17, 2002, Lynx Therapeutics, Inc. (the “Company”) issued a press release announcing that Richard P. Woychik, Ph.D., its Chief Scientific Officer, has been selected as the new director of The Jackson Laboratory in Bar Harbor, Maine. It is expected that Dr. Woychik will assume his role at The Jackson Laboratory in August. Dr. Woychik will be appointed to Lynx’s Board of Directors in order to accommodate his interest in staying connected with the development and application of Lynx’s technologies. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

On June 17, 2002, the Company also issued a press release announcing the addition of Thomas J. Vasicek, Ph.D., as Vice President, Business Development. Dr. Vasicek joins Lynx as a member of the senior management team and will lead the business development efforts for Massively Parallel Signature Sequencing, or MPSSTM, and Protein ProFilerTM. A copy of the press release is attached as Exhibit 99.2 hereto and is incorporated by reference herein.

Item 7. Financial Statements and Exhibits

(c)  Exhibits

99.1	Press Release, dated June 17, 2002, entitled “Dr. Rick Woychik to Lead The Jackson Laboratory.”
99.2	Press Release, dated June 17, 2002, entitled “Dr. Tom Vasicek to Lead Lynx Business Development Efforts.”

INDEX TO EXHIBITS

99.1	Press Release, dated June 17, 2002, entitled “Dr. Rick Woychik to Lead The Jackson Laboratory.”
99.2	Press Release, dated June 17, 2002, entitled “Dr. Tom Vasicek to Lead Lynx Business Development Efforts.”

SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 18, 2002	Lynx Therapeutics, Inc.
	By:	/s/ Edward C. Albini Edward C. Albini Chief Financial Officer (Principal Financial and Accounting Officer)

EX-99.1 3 f82468exv99w1.txt EXHIBIT 99.1 EXHIBIT 99.1 DR. RICK WOYCHIK TO LEAD THE JACKSON LABORATORY - Will join Lynx Board of Directors - HAYWARD, CALIFORNIA - JUNE 17, 2002 - Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today that Richard P. Woychik, Ph.D., its Chief Scientific Officer, has been selected as the new director of The Jackson Laboratory in Bar Harbor, Maine. It is expected that Dr. Woychik will assume his role at The Jackson Laboratory in August. Dr. Woychik will be appointed to Lynx's Board of Directors in order to accommodate his interest in staying connected with the development and application of Lynx's technologies. "The opportunity at The Jackson Laboratory was simply one that I could not forgo given my scientific background and interests in mammalian genetics," said Dr. Woychik. "I believe that my new role will allow my continued involvement in expanding scientific programs where MPSS(TM) is applied in systems biology research. There is no question in my mind that Sydney Brenner was right on target when he first conceived of this technology several years ago as a new paradigm for gene expression analysis. Obviously, I'm thrilled to be in a position to remain actively involved with Lynx, and to continue as an ardent supporter of its technologies." "We are excited for Rick in his new role at The Jackson Laboratory. It is a great fit given that he is a world-renowned mouse geneticist, with an impressive background in both academia and industry," said Kevin P. Corcoran, Lynx's President and Chief Executive Officer. "We are pleased that he will continue to be a great asset to Lynx through his active involvement on our Board." The Jackson Laboratory, founded in 1929, is a world leader in mammalian genetics research. The nonprofit, independent facility has a mission to improve the quality of human life through discoveries arising from its own genetic research and by enabling the research and education of others. Since 1989, The Jackson Laboratory's annual budget and federal research grants have quadrupled to $114 million and $50 million respectively, and its staff has doubled to more than 1,200 employees. With 34 research groups studying a wide range of diseases and disorders, as well as development, aging, and bioinformatics, The Jackson Laboratory is the world's largest mammalian genetics research institution. Lynx is a leader in the development and application of novel technologies for the discovery of gene expression patterns important to the pharmaceutical, biotechnology and agricultural industries. These technologies are based on the Megaclone(TM) technology, Lynx's unique and proprietary cloning procedure, which transforms a sample containing millions of DNA molecules into one made up of millions of micro-beads, each of which carries approximately 100,000 copies of one of the DNA molecules in the sample. Megaclone(TM) technology and Massively Parallel Signature Sequencing, or MPSS(TM), together provide comprehensive and quantitative digital gene expression data important to modern systems biology research. Lynx is also developing a proteomics technology, Protein ProFiler(TM), which is expected to provide high-resolution analysis of complex mixtures of proteins from cells or tissues. For more information, visit Lynx's web site at www.lynxgen.com. This press release contains "forward-looking" statements, including statements related to Lynx's ability to attract and retain key personnel, the Company's business strategy and the expansion of the Company's commercial applications of its technologies. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Lynx to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2001. Lynx does not undertake any obligation to update forward-looking statements. EX-99.2 4 f82468exv99w2.txt EXHIBIT 99.2 EXHIBIT 99.2 DR. TOM VASICEK TO LEAD LYNX BUSINESS DEVELOPMENT EFFORTS - - Fortifies senior management team and pushes commercialization of MPSS(TM) and Protein ProFiler(TM) - HAYWARD, CALIFORNIA - JUNE 17, 2002 - Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today the addition of Thomas J. Vasicek, Ph.D., as Vice President, Business Development. Dr. Vasicek joins Lynx as a member of the senior management team and will lead the business development efforts for Massively Parallel Signature Sequencing, or MPSS(TM), and Protein ProFiler(TM). Dr. Vasicek brings to Lynx considerable technical and business expertise in the field of gene expression analysis. In his prior roles, he has developed business and marketing platforms that have captured the interest of customers in the pharmaceutical, agricultural and biotechnology industries, as well as investigators working in academic research laboratories. Dr. Vasicek managed an interdisciplinary team of scientists at Millennium Pharmaceuticals to develop and use DNA microarray technologies for high throughput target discovery and drug development. In this capacity, he also played an important role on the teams that developed and managed several of Millennium's alliances with large pharmaceutical and agricultural companies. He was then recruited to the Corning Advanced Life Sciences Products Division, where as the Director, Commercial Technology, he managed the effort that established Corning's commercial DNA microarray capabilities and completed several major collaborations. Dr. Vasicek continued to expand his business expertise as Chief Scientific Officer at LabSeek Scientific Collaborative. In this capacity, he developed exclusive partnerships with several Fortune 100 companies. Coupled with his experience in business, Dr. Vasicek comes with formal training in chemistry and molecular biology at the Massachusetts Institute of Technology (B.S.), Harvard Medical School (Ph.D.), and Princeton University (Postdoctoral). "We believe that Tom brings with him a wealth of experience in the business of expression profiling, and are very excited to have him on the Lynx team," said Kevin P. Corcoran, Lynx's President and Chief Executive Officer. "He clearly understands the needs in the marketplace for the MPSS(TM) and Protein ProFiler(TM) technologies, particularly with potential customers that have an interest in systems biology research. We anticipate that Tom will broaden our customer base for these technologies in the business and academic research communities." Lynx is a leader in the development and application of novel technologies for the discovery of gene expression patterns important to the pharmaceutical, biotechnology and agricultural industries. These technologies are based on the Megaclone(TM) technology, Lynx's unique and proprietary cloning procedure, which transforms a sample containing millions of DNA molecules into one made up of millions of micro-beads, each of which carries approximately 100,000 copies of one of the DNA molecules in the sample. Megaclone(TM) technology and MPSS(TM) together provide comprehensive and quantitative digital gene expression data important to modern systems biology research. Lynx is also developing a proteomics technology, Protein ProFiler(TM), which is expected to provide high-resolution analysis of complex mixtures of proteins from cells or tissues. For more information, visit Lynx's web site at www.lynxgen.com. This press release contains "forward-looking" statements, including statements related to Lynx's ability to attract and retain key personnel, the future effectiveness of the Company's employees, the Company's business strategy and the expansion of the Company's commercial applications of its technologies. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Lynx to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2001. Lynx does not undertake any obligation to update forward-looking statements. -----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

                                                                    EXHIBIT 99.1


                 DR. RICK WOYCHIK TO LEAD THE JACKSON LABORATORY
                      - Will join Lynx Board of Directors -


HAYWARD, CALIFORNIA - JUNE 17, 2002 - Lynx Therapeutics, Inc. (Nasdaq: LYNX)
announced today that Richard P. Woychik, Ph.D., its Chief Scientific Officer,
has been selected as the new director of The Jackson Laboratory in Bar Harbor,
Maine. It is expected that Dr. Woychik will assume his role at The Jackson
Laboratory in August. Dr. Woychik will be appointed to Lynx's Board of Directors
in order to accommodate his interest in staying connected with the development
and application of Lynx's technologies.

"The opportunity at The Jackson Laboratory was simply one that I could not forgo
given my scientific background and interests in mammalian genetics," said Dr.
Woychik. "I believe that my new role will allow my continued involvement in
expanding scientific programs where MPSS(TM) is applied in systems biology
research. There is no question in my mind that Sydney Brenner was right on
target when he first conceived of this technology several years ago as a new
paradigm for gene expression analysis. Obviously, I'm thrilled to be in a
position to remain actively involved with Lynx, and to continue as an ardent
supporter of its technologies."

"We are excited for Rick in his new role at The Jackson Laboratory. It is a
great fit given that he is a world-renowned mouse geneticist, with an impressive
background in both academia and industry," said Kevin P. Corcoran, Lynx's
President and Chief Executive Officer. "We are pleased that he will continue to
be a great asset to Lynx through his active involvement on our Board."

The Jackson Laboratory, founded in 1929, is a world leader in mammalian genetics
research. The nonprofit, independent facility has a mission to improve the
quality of human life through discoveries arising from its own genetic research
and by enabling the research and education of others. Since 1989, The Jackson
Laboratory's annual budget and federal research grants have quadrupled to $114
million and $50 million respectively, and its staff has doubled to more than
1,200 employees. With 34 research groups studying a wide range of diseases and
disorders, as well as development, aging, and bioinformatics, The Jackson
Laboratory is the world's largest mammalian genetics research institution.

Lynx is a leader in the development and application of novel technologies for
the discovery of gene expression patterns important to the pharmaceutical,
biotechnology and agricultural industries. These technologies are based on the
Megaclone(TM) technology, Lynx's unique and proprietary cloning procedure, which
transforms a sample containing millions of DNA molecules into one made up of
millions of micro-beads, each of which carries approximately 100,000 copies of
one of the DNA molecules in the sample. Megaclone(TM) technology and Massively
Parallel Signature Sequencing, or MPSS(TM), together provide comprehensive and
quantitative digital gene expression data important to modern systems biology
research. Lynx is also developing a proteomics technology, Protein ProFiler(TM),
which is expected to provide high-resolution analysis of complex mixtures of
proteins from cells or tissues. For more information, visit Lynx's web site at
www.lynxgen.com.

This press release contains "forward-looking" statements, including statements
related to Lynx's ability to attract and retain key personnel, the Company's
business strategy and the expansion of the Company's commercial applications of
its technologies. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "predicts," "expects,"
"estimates," "intends," "will," "continue," "may," "potential," "should,"
"confident" and similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could cause the results
of Lynx to differ materially from those indicated by these forward-looking
statements, including, among others, risks detailed from time to time in the
Company's SEC reports, including its Annual Report on Form 10-K for the year
ended December 31, 2001. Lynx does not undertake any obligation to update
forward-looking statements.

EX-99.2

                                                                    EXHIBIT 99.2


            DR. TOM VASICEK TO LEAD LYNX BUSINESS DEVELOPMENT EFFORTS
- - Fortifies senior management team and pushes commercialization of MPSS(TM) and
Protein ProFiler(TM) -

HAYWARD, CALIFORNIA - JUNE 17, 2002 - Lynx Therapeutics, Inc. (Nasdaq: LYNX)
announced today the addition of Thomas J. Vasicek, Ph.D., as Vice President,
Business Development. Dr. Vasicek joins Lynx as a member of the senior
management team and will lead the business development efforts for Massively
Parallel Signature Sequencing, or MPSS(TM), and Protein ProFiler(TM). Dr.
Vasicek brings to Lynx considerable technical and business expertise in the
field of gene expression analysis. In his prior roles, he has developed business
and marketing platforms that have captured the interest of customers in the
pharmaceutical, agricultural and biotechnology industries, as well as
investigators working in academic research laboratories.

Dr. Vasicek managed an interdisciplinary team of scientists at Millennium
Pharmaceuticals to develop and use DNA microarray technologies for high
throughput target discovery and drug development. In this capacity, he also
played an important role on the teams that developed and managed several of
Millennium's alliances with large pharmaceutical and agricultural companies. He
was then recruited to the Corning Advanced Life Sciences Products Division,
where as the Director, Commercial Technology, he managed the effort that
established Corning's commercial DNA microarray capabilities and completed
several major collaborations. Dr. Vasicek continued to expand his business
expertise as Chief Scientific Officer at LabSeek Scientific Collaborative. In
this capacity, he developed exclusive partnerships with several Fortune 100
companies. Coupled with his experience in business, Dr. Vasicek comes with
formal training in chemistry and molecular biology at the Massachusetts
Institute of Technology (B.S.), Harvard Medical School (Ph.D.), and Princeton
University (Postdoctoral).

"We believe that Tom brings with him a wealth of experience in the business of
expression profiling, and are very excited to have him on the Lynx team," said
Kevin P. Corcoran, Lynx's President and Chief Executive Officer. "He clearly
understands the needs in the marketplace for the MPSS(TM) and Protein
ProFiler(TM) technologies, particularly with potential customers that have an
interest in systems biology research. We anticipate that Tom will broaden our
customer base for these technologies in the business and academic research
communities."

Lynx is a leader in the development and application of novel technologies for
the discovery of gene expression patterns important to the pharmaceutical,
biotechnology and agricultural industries. These technologies are based on the
Megaclone(TM) technology, Lynx's unique and proprietary cloning procedure, which
transforms a sample containing millions of DNA molecules into one made up of
millions of micro-beads, each of which carries approximately 100,000 copies of
one of the DNA molecules in the sample. Megaclone(TM) technology and MPSS(TM)
together provide comprehensive and quantitative digital gene expression data
important to modern systems biology research. Lynx is also developing a
proteomics technology, Protein ProFiler(TM), which is expected to provide
high-resolution analysis of complex mixtures of proteins from cells or tissues.
For more information, visit Lynx's web site at www.lynxgen.com.

This press release contains "forward-looking" statements, including statements
related to Lynx's ability to attract and retain key personnel, the future
effectiveness of the Company's employees, the Company's business strategy and
the expansion of the Company's commercial applications of its technologies. Any
statements contained in this press release that are not statements of historical
fact may be deemed to be forward-looking statements. Words such as "believes,"
"anticipates," "plans," "predicts," "expects," "estimates," "intends," "will,"
"continue," "may," "potential," "should," "confident" and similar expressions
are intended to identify forward-looking statements. There are a number of
important factors that could cause the results of Lynx to differ materially from
those indicated by these forward-looking statements, including, among others,
risks detailed from time to time in the Company's SEC reports, including its
Annual Report on Form 10-K for the year ended December 31, 2001. Lynx does not
undertake any obligation to update forward-looking statements.